Literature DB >> 17434618

HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.

Noriko Kuwahara1, Susumu Sasaki, Miyuki Kobara, Tetsuo Nakata, Tetsuya Tatsumi, Hidekazu Irie, Hiromichi Narumiya, Tsuguru Hatta, Kazuo Takeda, Hiroaki Matsubara, Shinji Hushiki.   

Abstract

BACKGROUND: The klotho gene and its protein product are mainly expressed in the kidney. The klotho protein induces suppression of multiple aging-related phenotypes, and homozygous klotho gene mutant mice display various senescent morbidity. Chronic inhibition of nitric oxide synthase (NOS) induces arteriosclerosis, while HMG-CoA reductase inhibitors (statins) have pleiotropic vascular protective effects besides cholesterol lowering. Therefore, the present studies were performed to determine whether chronic NOS blockade would affect anti-ageing klotho protein expression. In addition, the effects of statins on klotho protein expression and arteriosclerosis in these rats were investigated.
METHODS: Forty-two rats were divided into 6 groups as follows: (1) control, (2) NOS blockade, (3) atorvastatin (10 mg/kg/day), (4) pitavastatin (3 mg/kg/day), (5) NOS blockade+atorvastatin, (6) NOS blockade+pitavastatin. To induce arteriosclerosis further, a cuff was placed around the left femoral artery in each rat. After 4 weeks observation, rats were killed and renal klotho expression and the level of arteriosclerosis were examined.
RESULTS: The rats of chronic NOS inhibition developed hypertension, while statin treatment did not affect blood pressure in the rats with or without NOS blockade. Despite statin treatment, plasma levels of lipids did not differ among 6 groups. Immunohistochemical staining revealed that klotho protein was localized in the renal tubules. Chronic NOS inhibition markedly reduced renal klotho protein expression, while treatment with atorvastatin or pitavastatin completely prevented the reduction of klotho expression induced by NOS inhibition. In addition, statin treatment significantly improved arteriosclerotic lesions induced by NOS inhibition and cuff placement.
CONCLUSION: Since statin treatment did not alter blood pressure or serum lipid profiles, a novel vascular protective effect of statins via enhancing anti-aging klotho protein expression is suggested.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434618     DOI: 10.1016/j.ijcard.2007.02.029

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  21 in total

1.  Identification of novel small molecules that elevate Klotho expression.

Authors:  Gwendalyn D King; CiDi Chen; Mickey M Huang; Ella Zeldich; Patricia L Brazee; Eli R Schuman; Maxime Robin; Gregory D Cuny; Marcie A Glicksman; Carmela R Abraham
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

2.  Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.

Authors:  Yu Ah Hong; Ji Hee Lim; Min Young Kim; Yaeni Kim; Keun Suk Yang; Byung Ha Chung; Sungjin Chung; Bum Soon Choi; Chul Woo Yang; Yong-Soo Kim; Yoon Sik Chang; Cheol Whee Park
Journal:  Clin Exp Nephrol       Date:  2014-04-01       Impact factor: 2.801

Review 3.  Secreted klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 4.  αKlotho-FGF23 interactions and their role in kidney disease: a molecular insight.

Authors:  Edward R Smith; Stephen G Holt; Tim D Hewitson
Journal:  Cell Mol Life Sci       Date:  2019-07-26       Impact factor: 9.261

5.  Cardiovascular risk factors cause premature rarefaction of the collateral circulation and greater ischemic tissue injury.

Authors:  Scott M Moore; Hua Zhang; Nobuyo Maeda; Claire M Doerschuk; James E Faber
Journal:  Angiogenesis       Date:  2015-04-11       Impact factor: 9.596

6.  Klotho preservation by Rhein promotes toll-like receptor 4 proteolysis and attenuates lipopolysaccharide-induced acute kidney injury.

Authors:  Fangfang Bi; Fang Chen; Yanning Li; Ai Wei; Wangsen Cao
Journal:  J Mol Med (Berl)       Date:  2018-05-05       Impact factor: 4.599

7.  Therapeutic perspectives.

Authors:  Carmelo E Fiore; Pietra Pennisi; Marianna Tinè
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

Review 8.  Molecular basis of Klotho: from gene to function in aging.

Authors:  Yuechi Xu; Zhongjie Sun
Journal:  Endocr Rev       Date:  2015-02-19       Impact factor: 19.871

Review 9.  Current understanding of klotho.

Authors:  Yuhong Wang; Zhongjie Sun
Journal:  Ageing Res Rev       Date:  2008-10-31       Impact factor: 10.895

10.  A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.

Authors:  Masashi Kitagawa; Hitoshi Sugiyama; Hiroshi Morinaga; Tatsuyuki Inoue; Keiichi Takiue; Ayu Ogawa; Toshio Yamanari; Yoko Kikumoto; Haruhito Adam Uchida; Shinji Kitamura; Yohei Maeshima; Kazufumi Nakamura; Hiroshi Ito; Hirofumi Makino
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.